Zacks Investment Research
24 Dec 2025, 16:56 UTC · 38w ago
Verdict
Headline leans bullish. We score INSM +1.00 across five claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish
The biotech sector rallied 26% in the six months leading up to late December 2025, outperforming the S&P 500.
More positive than 91% of claims this week
Drug pricing agreements between large drugmakers and the Trump administration have improved industry policies.
So whatRegulatory certainty regarding pricing removes a major systemic headwind for pharmaceutical valuations.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 85% of claims this week
Mineralys Therapeutics' drug candidate lorundrostat met primary efficacy endpoints in Phase III and Phase II studies for hypertension.
More positive than 77% of claims this week
Strong M&A activity is expected to continue across the drug and biotech industry into 2026.
So whatOngoing M&A provides a valuation floor and potential premiums for mid-to-small cap biotech companies.
More positive than 65% of claims this week
The FDA approved 44 novel therapies as of December 22, 2025.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Identified as a top biotech stock with over 50% returns this year and potential for more growth in 2026.
More positive than 99% of ticker scores this week
Identified as a top biotech stock with over 50% returns this year and potential for more growth in 2026.
More positive than 99% of ticker scores this week
The stock has returned over 50% this year, has a promising pipeline, and reported positive efficacy endpoints for lorundrostat.
More positive than 99% of ticker scores this week
Identified as a top biotech stock with over 50% returns this year and potential for more growth in 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
7h ago
−29.9%
Price is moving against the score
$123.96 vs $176.77 close before publication (Dec 23) · not market-adjusted
INSM chart →
